A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder

Trial Profile

A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Fluvoxamine (Primary)
  • Indications Obsessive-compulsive disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 03 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 25 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Aug 2016, according to ClinicalTrials.gov record.
    • 31 Aug 2015 Planned End Date changed from 1 Dec 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top